Literature DB >> 15958835

Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France.

Olivier Lortholary1, Arnaud Fontanet, Nathalie Mémain, Antoine Martin, Karine Sitbon, Françoise Dromer.   

Abstract

BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS) in association with cryptococcosis has been anecdotically reported following administration of highly active antiretroviral therapy (HAART).
OBJECTIVE: To analyse the incidence and risk factors for IRIS-associated cryptococcosis among HIV-infected patients.
DESIGN: Retrospective multicentre study between 1996 and 2000 through the French Cryptococcosis Database.
METHODS: Subsequent occurrence of IRIS examined in 120 HIV-infected adult patients treated with HAART and experiencing a first episode of culture-confirmed cryptococcosis.
RESULTS: Ten patients developed IRIS during the study period, giving an incidence of 10/239, or 4.2/100 person-years [95% confidence interval (CI), 2.2-7.8]. IRIS consisted of acute symptoms consistent with inflammation occurring within a median of 8 months (range, 2-37) after the diagnosis of cryptococcosis in the context of negative cultures and immunological and/or virological response to HAART. Radiology and histopathology detected features compatible with inflammation. Symptom severity required transfer into intensive care units for three patients and use of anti-inflammatory drugs for four. Three patients with evolutive IRIS died. Compared with patients without IRIS for whom complete clinical and microbiological information were available at baseline, previously unknown HIV infection [odds ratio (OR), 4.8; 95% CI, 1.0-21.7], CD4 cell count < 7 x 10 cells/l (OR, 4.0; 95% CI, 0.9-17.2), fungaemia (OR, 6.1; 95% CI, 1.1-35.2) and HAART initiation within 2 months of cryptococcosis diagnosis (OR, 5.50; 95% CI, 1.0-29.6) were independently associated with the risk of subsequent IRIS.
CONCLUSIONS: IRIS-related cryptococcosis was observed more frequently in severely immunocompromised patients with disseminated infection and HAART initiation soon after the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958835     DOI: 10.1097/01.aids.0000174450.70874.30

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  94 in total

Review 1.  Management of cryptococcal meningitis in sub-saharan Africa.

Authors:  Arthur Jackson; Mina C Hosseinipour
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

2.  Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras.

Authors:  Vincent Peigne; Françoise Dromer; Caroline Elie; Olivier Lidove; Olivier Lortholary
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

Review 3.  When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!

Authors:  Philip M Grant; Andrew R Zolopa
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

Review 4.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

5.  A case for treating high hepatitis B DNA levels before starting HIV therapy.

Authors:  Jason V Baker; David R Boulware; Paul R Bohjanen
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

6.  Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico.

Authors:  Irma Hoyo-Ulloa; Pablo F Belaunzarán-Zamudio; Brenda Crabtree-Ramirez; Arturo Galindo-Fraga; María Eugenia Pérez-Aguinaga; Juan G Sierra-Madero
Journal:  Int J Infect Dis       Date:  2011-04-13       Impact factor: 3.623

Review 7.  Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses.

Authors:  N Singh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267

8.  Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome.

Authors:  Shuli Bonham; David B Meya; Paul R Bohjanen; David R Boulware
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

9.  Pediatric HIV immune reconstitution inflammatory syndrome.

Authors:  David R Boulware; Steven Callens; Savita Pahwa
Journal:  Curr Opin HIV AIDS       Date:  2008-07       Impact factor: 4.283

10.  Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database.

Authors:  H Byakwaga; K Petoumenos; J Ananworanich; F Zhang; M A Boyd; T Sirisanthana; P C K Li; C Lee; C V Mean; V Saphonn; S F S Omar; S Pujari; P Phanuphak; P L Lim; N Kumarasamy; Y M A Chen; T P Merati; S Sungkanuparph; R Ditangco; S Oka; G Tau; J Zhou; M G Law; S Emery
Journal:  J Int Assoc Provid AIDS Care       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.